SAN
DIEGO, May 8, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of
its Phase 1 first-in-human clinical study to evaluate the safety,
tolerability, pharmacokinetics, and pharmacodynamics of
investigational compound NBI-1117567 in healthy adult participants.
NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring)
selective muscarinic agonist for the potential treatment of
neurological and neuropsychiatric conditions.
"Neurocrine Biosciences has the largest muscarinic
portfolio in the industry, with compounds in development for
psychiatric and neurological disorders," said Eiry W. Roberts,
M.D., Chief Medical Officer at Neurocrine Biosciences. "As an M1
preferring M1/M4 agonist, NBI-1117567 has the potential to treat
symptoms of cognition in patients with neurological and
neuropsychiatric conditions where psychosis might also be
present."
About NBI-1117567
NBI-1117567 is an investigational,
oral, M1/M4 (M1 preferring) selective muscarinic agonist.
Muscarinic receptors are fundamental to activating signaling
pathways in the brain. There are five muscarinic acetylcholine
receptors involved in neurotransmission, two of which are
selectively targeted by NBI-1117567 (M1 preferring and M4), with M1
validated as a potential drug target in cognition and M4 in
psychosis. Neurocrine Biosciences acquired the rights to develop
and commercialize NBI-1117567 from Nxera Pharma (formerly Sosei
Heptares).
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused,
biopharmaceutical company with a simple purpose: to relieve
suffering for people with great needs, but few options. We are
dedicated to discovering and developing life-changing treatments
for patients with under-addressed neurological, neuroendocrine and
neuropsychiatric disorders. The company's diverse portfolio
includes FDA-approved treatments for tardive dyskinesia, chorea
associated with Huntington's disease, endometriosis* and uterine
fibroids*, as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more
information, visit neurocrine.com, and follow the company on
LinkedIn, X (formerly Twitter), and Facebook.
(*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences,
Inc.
Forward-Looking Statements
In addition to historical
facts, this press release contains forward-looking statements that
involve a number of risks and uncertainties. These statements
include, but are not limited to, statements related to the
potential benefits of NBI-1117567. Among the factors that could
cause actual results to differ materially from those indicated in
the forward-looking statements are: risks that clinical development
activities may not be initiated or completed on time or at all, or
may be delayed for regulatory, manufacturing, or other reasons, may
not be successful or replicate previous clinical trial results, may
fail to demonstrate that our product candidates are safe and
effective, or may not be predictive of real-world results or of
results in subsequent clinical trials; our future financial and
operating performance; risks associated with our dependence on
third parties for development, manufacturing, and commercialization
activities for our products and product candidates, and our ability
to manage these third parties; risks that the FDA or other
regulatory authorities may make adverse decisions regarding our
products or product candidates; risks that the potential benefits
of the agreements with our collaboration partners may never be
realized; risks that our products, and/or our product candidates
may be precluded from commercialization by the proprietary or
regulatory rights of third parties, or have unintended side
effects, adverse reactions or incidents of misuse; risks associated
with U.S. federal or state legislative or regulatory and/or policy
efforts which may result in, among other things, an adverse impact
on our revenues or potential revenue; risks associated with
potential generic entrants for our products; and other risks
described in the Company's periodic reports filed with the
Securities and Exchange Commission, including without limitation
the Company's quarterly report on Form 10-Q for the quarter
ended March 31, 2024. Neurocrine
Biosciences disclaims any obligation to update the statements
contained in this press release after the date hereof other than
required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-effects-of-nbi-1117567-in-healthy-adults-302138590.html
SOURCE Neurocrine Biosciences, Inc.